Shattuck Labs, Inc. Q3 FY2022 earnings call

• Clinical progress: SL-172154 (154) completed enrollment in monotherapy dose escalation for platinum-resistant ovarian cancer, reached 10 mg/kg; began enrolling in first chemotherapy combination cohort with liposomal doxorubicin at 3 mg/kg. Clinical trial for AML and MDS started, enrollment in azacitidine combination cohort in Q4 2022. • SL-279252 (252): Phase I trial ongoing, completing enrollment in 24 mg/kg cohort, top-line data expected Q1 2023. • GADLEN platform: Progress in preclinical studies, CD20 GADLEN completed toxicology study, B7-H3 GADLEN in development for solid tumors.

No specific financial performance data for product segments in terms of absolute revenue and contribution % provided in the transcript.

• Existing cash and cash equivalents and investments of approximately $185.1 million expected to fund operations into the second half of 2024. • Clinical data readouts for 154 and 252 trials expected in 2023.

• Forward-looking statements involve risks and uncertainties; refer to most recent Annual Report on Form 10-K for the year ended December 31, 2021, and other SEC filings for details.

Q: Last quarter talked about 3 milligram dose in doxo combo trial, any data on 10-milligram dose in combo?

A: PK/PD analyses support 3 mg per kilogram dose in combination, protocol allows dose escalation but 3 mg is solid.

Q: Infusion reactions in monotherapy, update on combo trials?

A: Using longer infusion time (two hours) in combo trials.

Q: On SL-154 monotherapy trial in platinum-resistant ovarian cancer, sign of toxicity at 10 mg/kg?

A: Decision based on PK/PD, 3 mg per kg dose gives full receptor occupancy and on-target activity.

Q: On 154 in AML and MDS, patient numbers and efficacy in azacitidine combo?

A: Anticipate 10-20 patients in dose escalation, complete remissions in relapsed/refractory population would be differentiating.

Q: Change in combo from venetoclax to azacitidine?

A: Dose escalation with azacitidine, followed by expansion with azacitidine and venetoclax.

Q: Difference between CD47 axis and ILT4 targeting?

A: CD47 axis addresses macrophage phagocytosis aspect, CD40 stimulation guides macrophage to M1 phenotype; ILT4 agents act differently.

Q: GADLEN as partnering opportunity?

A: GADLEN platform is broad, B7-H3 GADLEN in development for solid tumors, potential for partnering.

Q: Details on 3 mg and 10 mg dose APD dynamics?

A: 3 mg per kg dose shows full receptor occupancy and maximal pharmacodynamic effects, 10 mg doesn't provide additional benefit.

Q: Combination with folate receptor ADC?

A: Opportunity to potentiate initial tumor killing signal from mirvetuximab, await accelerated approval.

Q: 252 program wind down if not seeing 20% response?

A: Operating assumption is if not seeing 20% response, program will wind down.